Pharmacolog Appoints New Sales and Marketing Manager
Pharmacolog appoints Kent Öbrink as new Sales and Marketing Manager. Kent has more than 20 years of experience in qualified healthcare sales and a solid international experience. Kent will start on 1 of June and comes from C-Rad AB, where he held the role of Global Sales Manager.
As sales and marketing manager, Kent Öbrink will be responsible for the company’s commercial activities and for collecting important market intelligence before new development projects. Kent is a qualified microbiologist, but soon entered sales and marketing with a job as a Sales Representative at Kabi Pharmacia in 1991. After that, Kent held several qualified sales manager positions within the company until 1999, when he was recruited as sales manager at Fresenius-Kabi. For the past seven years, Kent has worked at C-Rad AB and has been instrumental in developing C-Rad’s sales and marketing organization. During the past four years, he has been acting as Global Sales Manager with responsibility for Europe and the United States.
CEO Mats Högberg comments. “With Kent at the helm of our sales and marketing activities, we are very well equipped to accelerate our commercial activities both internationally and nationally. Kent has a very relevant experience and competence profile for us. With his long experience of working with the sale of innovative technology in small and medium-sized companies in an international market, Kent will be a very valuable addition to our team of experts.”
Successful collaboration with Swedish university hospital enters the next phase
Pharmacolog has, in collaboration with one of the leading university hospitals in Sweden, developed ARM (Advanced Reconstruction Module). The system will be tested in clinical environments for 6 months and comprises 2 DrugLog systems that will be rented during the project period.
Astrid Lindgren’s Children’s Hospital at Karolinska University Hospital will with funding from SLL Innovation to undertake a 6-month project to test the Advanced Reconstruction Module (ARM) with its associated DrugLog® in a clinical environment. The project runs throughout the year and includes the lease of two DrugLog systems.
The ARM, partly funded by Vinnova, was implemented during the second half o...
New company analysis of Pharmacolog AB performed by Jarl Securities. Read the complete analysis here (in Swedish only): https://www.aktiespararna.se/sites/default/files/pharmacolog_2017-06-13.pdf
Pharmacolog signs a collaboration agreement with researchers at Uppsala University regarding antibiotic treatment
Pharmacolog AB has entered a research and development cooperation with researchers from Uppsala University regarding methods for determining antibiotic concentration in the blood during treatment of patients with severe infections.
Antibiotic treatment with the right dose is crucial for patients to survive severe infections. Today, technology is lacking to quickly determine blood concentrations of antibiotics in patients treated for serious infections. The collaboration between Pharmacolog AB and Professor Miklos Lipcsey at the Department of Surgical Sciences and Professor Anders Larsson at the Department of Medical Sciences, both at Uppsala University, is a result of preparatory tests of the abi...
Pharmacolog’s distributor has ordered a first system to be placed at Hôspital du Confluent in Nantes. The system shall be used for the final control of chemotherapy drugs toxicity at the hospital pharmacy. Pharmed won the order in competition with other suppliers.
During 2016, Pharmed has deliberately processed the French market, focusing on hospital pharmacies that prepare for chemotherapy and has now placed the first order on a DrugLog system. The system will be placed at the Hôspital du Confluent in Nantes and will be used for the final control of chemotherapy drugs prepared made at the hospital pharmacy. The deal means that, according to agreement, Pharmed purchases a DrugLog® systems f...